Trenbolone Cycle for recomp

[JC.Costa]

PED Cycle Report: Trenbolone Enanthate, Testosterone (Sustanon), and Semaglutide​

1. Starting Stats​

• Age: 30 years old.
• Height: 186 cm (6'1").
• Body weight: Approximately 95 kg around the period of the cycle, with a current body weight of 89 kg.
• Body fat: Approximately 16–18%, currently 11%
• Goal: Body recomposition, maintaining or increasing lean muscle mass while keeping body fat relatively low.

I have an established resistance-training background and follow a structured workout routine focused on muscle development, strength, and body composition. My overall approach combines resistance training, cardio, a high-protein diet, and pharmacological support for testosterone replacement and weight management.

2. PEDs Protocol​

Testosterone — Sustanon 250​

• Compound: Sustanon 250, a blend of testosterone esters.
• Dose: 250 mg per administration.
• Frequency: Every 10 days.
• Purpose: Ongoing testosterone replacement therapy (TRT).
• Status: Continued throughout the trenbolone cycle and after its discontinuation.

Testosterone was already part of my ongoing TRT protocol and was not introduced exclusively for this cycle. I continued administering Sustanon 250 every 10 days throughout the period described.

Trenbolone Enanthate​

• Compound: Trenbolone enanthate.
• Dose: Approximately 400 mg per week.
• Duration: Six weeks.
• Administration: Intramuscular injections twice per week, on Tuesdays and Fridays.
• Concentration: 200 mg/mL.
• Status: Discontinued after six weeks.

I administered trenbolone enanthate twice weekly, on Tuesdays and Fridays, for a total of six weeks. On one documented occasion, I administered approximately 0.8 mL of trenbolone enanthate at a concentration of 200 mg/mL, equivalent to 160 mg, alongside 1 mL of Sustanon 250.
Following one injection into the medial deltoid, I experienced localized swelling, hardness, and pain at the injection site.

Semaglutide​

• Compound: Semaglutide.
• Dose: 2 mg per week.
• Frequency: Once weekly.
• Total duration: 10 weeks.
• Start date: One week before starting trenbolone enanthate.
• Purpose: Appetite control, weight management, and support for body-composition goals.

I started semaglutide at 2 mg per week one week before beginning the six-week trenbolone enanthate cycle. I continued semaglutide throughout the trenbolone cycle and for several weeks after discontinuing trenbolone, completing a total of 10 weeks of semaglutide use.
My objective was to support appetite control and body-weight management while maintaining my resistance-training routine and high-protein diet.

Combined Protocol Timeline​

• Week 1: Semaglutide at 2 mg per week, before starting trenbolone.
• Weeks 2–7: Semaglutide at 2 mg per week alongside trenbolone enanthate at approximately 400 mg per week. Trenbolone injections were administered on Tuesdays and Fridays. Sustanon 250 continued every 10 days as ongoing TRT.
• Weeks 8–10: Semaglutide continued after the six-week trenbolone cycle had ended. Sustanon TRT remained ongoing.

This timeline reflects the reported durations and the fact that semaglutide was started one week before trenbolone.

Other PEDs, Ancillaries, and Medications​

• Other anabolic steroids: No additional anabolic compounds were confirmed as part of this cycle.
• Primobolan (methenolone): Discussed as a possible option, but actual use was not confirmed.
• Additional fat burners: No confirmed use documented.
• Thyroid medications: No confirmed use documented.
• Aromatase inhibitors or other hormonal ancillaries: No confirmed use documented.
• Post-cycle therapy (PCT): No separate PCT protocol documented. I continued my established TRT with Sustanon.

3. Training and Nutrition​

Training Routine​

I follow a six-day training split focused on hypertrophy, strength, and overall physique development.

• Monday: Chest and triceps.
• Tuesday: Treadmill cardio, biceps, and abs.
• Wednesday: Glutes, hamstrings, and shoulders.
• Thursday: Treadmill cardio, triceps, and abs.
• Friday: Back and biceps.
• Saturday: Quadriceps and shoulders.
• Sunday: Rest or recovery.

My cardio routine has included treadmill sessions, with a target of approximately 30 minutes at 6.5 km/h. I have also worked on improving my continuous running performance, including running at approximately 8.5 km/h for 2 km.
My training priorities are to preserve muscle mass, improve strength, and manage body fat while maintaining a consistent exercise schedule.

Nutrition​

My nutrition approach prioritizes a high protein intake to support muscle maintenance and growth. My previously established protein target was approximately 200 g per day.
My regular meals include chicken, rice, lean or shredded beef, protein shakes, and wraps containing chicken and mozzarella. I focus on practical meals that help me maintain a consistent protein intake while managing body composition.
Semaglutide was incorporated into my weight-management approach to support appetite control. However, I do not have a complete record of daily calorie intake, carbohydrate and fat intake, or the precise dietary changes made during the cycle.

Supplements and Support Products​

My documented nutrition approach included protein supplementation. A complete list of supplements and their doses during the cycle is not available.
I have also discussed Mounjaro (tirzepatide) in the context of weight management, but its use during this specific cycle was not confirmed. It should therefore not be considered part of the confirmed protocol described here.

4. Progress, Side Effects, and General Experience​

Training and Physical Progress​

I maintained my regular resistance-training routine during the period discussed. My broader goals were to preserve training performance, maintain muscle mass, and manage body fat.
My recorded body weight was approximately 94–95 kg around the relevant period, and my current body weight is 89 kg. My previously estimated body fat was approximately 16–18%.
However, I do not have sufficiently detailed measurements to quantify the exact changes in lean mass, body fat, or strength attributable specifically to this cycle. I cannot confidently distinguish the individual contributions of training, nutrition, semaglutide, testosterone, and trenbolone to the changes in body composition.

Injection-Site Reaction​

Following an intramuscular injection into the medial deltoid, I experienced localized swelling, hardness, and pain at the injection site. This was a notable physical reaction during the period of use.

Hair Shedding​

I noticed increased hair shedding, with more hair falling out in the shower, on my pillow, and when running my hand through my hair. At the time, I did not observe an obvious change in my frontal hairline.
This was a noticeable change compared with my previous experience while using testosterone alone. The exact cause of the increased shedding was not established.

Laboratory Results and Cardiovascular Health​

My laboratory testing identified significant lipid abnormalities:

Marker	Result
LDL cholesterol	230 mg/dL
HDL cholesterol	23.8 mg/dL
LDL/HDL ratio	9.7
Hemoglobin	15.8 g/dL
Hematocrit	47.0%
Red blood cell count	5.41 million/µL
White blood cell count	6.7 thousand/µL
Platelet count	254 thousand/µL

The most concerning findings were my LDL cholesterol of 230 mg/dL and HDL cholesterol of 23.8 mg/dL. These values represent a markedly unfavorable lipid profile and warrant medical attention.
My physician recommended dietary adjustments. I planned to repeat my blood tests and review the results with my urologist to evaluate the persistence of these abnormalities and assess other relevant metabolic markers.
I am particularly interested in monitoring:

• Lipid profile: Total cholesterol, LDL, HDL, and triglycerides.
• Liver function: ALT/TGP, AST/TGO, GGT, alkaline phosphatase, and bilirubin.
• Blood count: Hemoglobin, hematocrit, and red blood cell count.
• Hormonal status: Relevant testosterone measurements and other tests as clinically indicated.
• Metabolic health: Glucose regulation and other relevant markers, particularly in the context of semaglutide use.

I do not have confirmed follow-up liver enzyme values in this report, so the extent of any liver enzyme changes cannot be quantified here.

5. Overall Experience and Lessons Learned​

The main concerns identified during this period were the injection-site reaction, increased hair shedding, and significant changes in my lipid profile.
Although body composition and training performance were important objectives, the laboratory abnormalities highlighted the importance of monitoring cardiovascular and metabolic health rather than evaluating a cycle solely on appearance, strength, or subjective well-being.
The simultaneous use of testosterone, trenbolone, and semaglutide also makes it difficult to attribute individual outcomes to a single compound. Trenbolone exposure, ongoing testosterone therapy, dietary changes, weight changes, and other factors may all influence different aspects of health and body composition.
If I were evaluating a similar protocol in the future, I would place greater emphasis on baseline laboratory testing, follow-up blood work, cardiovascular risk assessment, and medical supervision. I would also ensure that changes in weight, training performance, and laboratory markers were documented consistently enough to evaluate the overall outcome objectively.
Given the LDL and HDL results, addressing cardiovascular risk is a priority rather than assuming that the abnormalities will resolve automatically after discontinuation.

6. Final Protocol Summary​

My protocol consisted of the following:

• Testosterone (Sustanon 250): 250 mg every 10 days as ongoing TRT.
• Trenbolone enanthate: Approximately 400 mg per week for six weeks, administered intramuscularly on Tuesdays and Fridays.
• Semaglutide: 2 mg once weekly for 10 weeks, beginning one week before the trenbolone cycle and continuing beyond its completion.

I maintained a six-day resistance-training split, incorporated treadmill cardio, and followed a high-protein diet with a previously established target of approximately 200 g of protein per day.
My body weight decreased from approximately 95 kg around the period of the cycle to my current weight of 89 kg. The exact contributions of the compounds, nutrition, and training to this change have not been established.
The main documented concerns were localized injection-site inflammation, increased hair shedding, and a markedly unfavorable lipid profile, particularly elevated LDL and low HDL cholesterol. My priority is to monitor these findings through repeat laboratory testing and medical follow-up.

 

[Davy Tenebrae]

PED Cycle Report: Trenbolone Enanthate, Testosterone (Sustanon), and Semaglutide​

1. Starting Stats​

• Age: 30 years old.
• Height: 186 cm (6'1").
• Body weight: Approximately 95 kg around the period of the cycle, with a current body weight of 89 kg.
• Body fat: Approximately 16–18%, currently 11%
• Goal: Body recomposition, maintaining or increasing lean muscle mass while keeping body fat relatively low.

I have an established resistance-training background and follow a structured workout routine focused on muscle development, strength, and body composition. My overall approach combines resistance training, cardio, a high-protein diet, and pharmacological support for testosterone replacement and weight management.

2. PEDs Protocol​

Testosterone — Sustanon 250​

• Compound: Sustanon 250, a blend of testosterone esters.
• Dose: 250 mg per administration.
• Frequency: Every 10 days.
• Purpose: Ongoing testosterone replacement therapy (TRT).
• Status: Continued throughout the trenbolone cycle and after its discontinuation.

Testosterone was already part of my ongoing TRT protocol and was not introduced exclusively for this cycle. I continued administering Sustanon 250 every 10 days throughout the period described.

Trenbolone Enanthate​

• Compound: Trenbolone enanthate.
• Dose: Approximately 400 mg per week.
• Duration: Six weeks.
• Administration: Intramuscular injections twice per week, on Tuesdays and Fridays.
• Concentration: 200 mg/mL.
• Status: Discontinued after six weeks.

I administered trenbolone enanthate twice weekly, on Tuesdays and Fridays, for a total of six weeks. On one documented occasion, I administered approximately 0.8 mL of trenbolone enanthate at a concentration of 200 mg/mL, equivalent to 160 mg, alongside 1 mL of Sustanon 250.
Following one injection into the medial deltoid, I experienced localized swelling, hardness, and pain at the injection site.

Semaglutide​

• Compound: Semaglutide.
• Dose: 2 mg per week.
• Frequency: Once weekly.
• Total duration: 10 weeks.
• Start date: One week before starting trenbolone enanthate.
• Purpose: Appetite control, weight management, and support for body-composition goals.

I started semaglutide at 2 mg per week one week before beginning the six-week trenbolone enanthate cycle. I continued semaglutide throughout the trenbolone cycle and for several weeks after discontinuing trenbolone, completing a total of 10 weeks of semaglutide use.
My objective was to support appetite control and body-weight management while maintaining my resistance-training routine and high-protein diet.

Combined Protocol Timeline​

• Week 1: Semaglutide at 2 mg per week, before starting trenbolone.
• Weeks 2–7: Semaglutide at 2 mg per week alongside trenbolone enanthate at approximately 400 mg per week. Trenbolone injections were administered on Tuesdays and Fridays. Sustanon 250 continued every 10 days as ongoing TRT.
• Weeks 8–10: Semaglutide continued after the six-week trenbolone cycle had ended. Sustanon TRT remained ongoing.

This timeline reflects the reported durations and the fact that semaglutide was started one week before trenbolone.

Other PEDs, Ancillaries, and Medications​

• Other anabolic steroids: No additional anabolic compounds were confirmed as part of this cycle.
• Primobolan (methenolone): Discussed as a possible option, but actual use was not confirmed.
• Additional fat burners: No confirmed use documented.
• Thyroid medications: No confirmed use documented.
• Aromatase inhibitors or other hormonal ancillaries: No confirmed use documented.
• Post-cycle therapy (PCT): No separate PCT protocol documented. I continued my established TRT with Sustanon.

3. Training and Nutrition​

Training Routine​

I follow a six-day training split focused on hypertrophy, strength, and overall physique development.

• Monday: Chest and triceps.
• Tuesday: Treadmill cardio, biceps, and abs.
• Wednesday: Glutes, hamstrings, and shoulders.
• Thursday: Treadmill cardio, triceps, and abs.
• Friday: Back and biceps.
• Saturday: Quadriceps and shoulders.
• Sunday: Rest or recovery.

My cardio routine has included treadmill sessions, with a target of approximately 30 minutes at 6.5 km/h. I have also worked on improving my continuous running performance, including running at approximately 8.5 km/h for 2 km.
My training priorities are to preserve muscle mass, improve strength, and manage body fat while maintaining a consistent exercise schedule.

Nutrition​

My nutrition approach prioritizes a high protein intake to support muscle maintenance and growth. My previously established protein target was approximately 200 g per day.
My regular meals include chicken, rice, lean or shredded beef, protein shakes, and wraps containing chicken and mozzarella. I focus on practical meals that help me maintain a consistent protein intake while managing body composition.
Semaglutide was incorporated into my weight-management approach to support appetite control. However, I do not have a complete record of daily calorie intake, carbohydrate and fat intake, or the precise dietary changes made during the cycle.

Supplements and Support Products​

My documented nutrition approach included protein supplementation. A complete list of supplements and their doses during the cycle is not available.
I have also discussed Mounjaro (tirzepatide) in the context of weight management, but its use during this specific cycle was not confirmed. It should therefore not be considered part of the confirmed protocol described here.

4. Progress, Side Effects, and General Experience​

Training and Physical Progress​

I maintained my regular resistance-training routine during the period discussed. My broader goals were to preserve training performance, maintain muscle mass, and manage body fat.
My recorded body weight was approximately 94–95 kg around the relevant period, and my current body weight is 89 kg. My previously estimated body fat was approximately 16–18%.
However, I do not have sufficiently detailed measurements to quantify the exact changes in lean mass, body fat, or strength attributable specifically to this cycle. I cannot confidently distinguish the individual contributions of training, nutrition, semaglutide, testosterone, and trenbolone to the changes in body composition.

Injection-Site Reaction​

Following an intramuscular injection into the medial deltoid, I experienced localized swelling, hardness, and pain at the injection site. This was a notable physical reaction during the period of use.

Hair Shedding​

I noticed increased hair shedding, with more hair falling out in the shower, on my pillow, and when running my hand through my hair. At the time, I did not observe an obvious change in my frontal hairline.
This was a noticeable change compared with my previous experience while using testosterone alone. The exact cause of the increased shedding was not established.

Laboratory Results and Cardiovascular Health​

My laboratory testing identified significant lipid abnormalities:

Marker	Result
LDL cholesterol	230 mg/dL
HDL cholesterol	23.8 mg/dL
LDL/HDL ratio	9.7
Hemoglobin	15.8 g/dL
Hematocrit	47.0%
Red blood cell count	5.41 million/µL
White blood cell count	6.7 thousand/µL
Platelet count	254 thousand/µL

The most concerning findings were my LDL cholesterol of 230 mg/dL and HDL cholesterol of 23.8 mg/dL. These values represent a markedly unfavorable lipid profile and warrant medical attention.
My physician recommended dietary adjustments. I planned to repeat my blood tests and review the results with my urologist to evaluate the persistence of these abnormalities and assess other relevant metabolic markers.
I am particularly interested in monitoring:

• Lipid profile: Total cholesterol, LDL, HDL, and triglycerides.
• Liver function: ALT/TGP, AST/TGO, GGT, alkaline phosphatase, and bilirubin.
• Blood count: Hemoglobin, hematocrit, and red blood cell count.
• Hormonal status: Relevant testosterone measurements and other tests as clinically indicated.
• Metabolic health: Glucose regulation and other relevant markers, particularly in the context of semaglutide use.

I do not have confirmed follow-up liver enzyme values in this report, so the extent of any liver enzyme changes cannot be quantified here.

5. Overall Experience and Lessons Learned​

The main concerns identified during this period were the injection-site reaction, increased hair shedding, and significant changes in my lipid profile.
Although body composition and training performance were important objectives, the laboratory abnormalities highlighted the importance of monitoring cardiovascular and metabolic health rather than evaluating a cycle solely on appearance, strength, or subjective well-being.
The simultaneous use of testosterone, trenbolone, and semaglutide also makes it difficult to attribute individual outcomes to a single compound. Trenbolone exposure, ongoing testosterone therapy, dietary changes, weight changes, and other factors may all influence different aspects of health and body composition.
If I were evaluating a similar protocol in the future, I would place greater emphasis on baseline laboratory testing, follow-up blood work, cardiovascular risk assessment, and medical supervision. I would also ensure that changes in weight, training performance, and laboratory markers were documented consistently enough to evaluate the overall outcome objectively.
Given the LDL and HDL results, addressing cardiovascular risk is a priority rather than assuming that the abnormalities will resolve automatically after discontinuation.

6. Final Protocol Summary​

My protocol consisted of the following:

• Testosterone (Sustanon 250): 250 mg every 10 days as ongoing TRT.
• Trenbolone enanthate: Approximately 400 mg per week for six weeks, administered intramuscularly on Tuesdays and Fridays.
• Semaglutide: 2 mg once weekly for 10 weeks, beginning one week before the trenbolone cycle and continuing beyond its completion.

I maintained a six-day resistance-training split, incorporated treadmill cardio, and followed a high-protein diet with a previously established target of approximately 200 g of protein per day.
My body weight decreased from approximately 95 kg around the period of the cycle to my current weight of 89 kg. The exact contributions of the compounds, nutrition, and training to this change have not been established.
The main documented concerns were localized injection-site inflammation, increased hair shedding, and a markedly unfavorable lipid profile, particularly elevated LDL and low HDL cholesterol. My priority is to monitor these findings through repeat laboratory testing and medical follow-up.

Excellent log! Really appreciate how clearly you've documented your compounds, dosages, training routine and progress. That's exactly the kind of detailed reporting we like seeing in the community.
Impressive body composition changes so far! Just be careful with that LDL of 230 and HDL of 23.8, as those values deserve proper medical follow-up. Looking forward to seeing how you progress from here. Keep us updated!